Abstracts tagged "T Cell"

Abstract Number: 0084 • ACR Convergence 2023
Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function
Jeremy Morrissette¹, Vinh Dang², Jemy Varghese², Zachary Lanzar¹, Junior Nguyen², Emily Landy³, Anastasia Frank-Kamenetskii⁴ and Scott Canna², ¹University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴CHOP/UPENN, Philadelphia, PA
Background/Purpose: Interleukin 18 (IL-18) is an inflammasome-activated cytokine that canonically amplifies interferon-gamma (IFNg) production and cytotoxicity by CD8 T-cells (CD8Ts) and Th1 CD4 T-cells (CD4Ts).…
Abstract Number: 0692 • ACR Convergence 2023
Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity
Johannes Nowatzky¹, Ziyan Lin², Yesim Ozguler³, Alireza Khodadadi-Jamayran², Didar Ucar⁴, Aristotelis Tsirigos⁵, Gulen Hatemi⁶ and Olivier Manches⁷, ¹NYU Grossman School of Medicine, Department of Medicine, Department of Pathology, Division of Rheumatology, NYU Behçet's Disease Program, NYU Ocular Rheumatology Program, New York, NY, ²NYU Grossman School of Medicine, Applied Bioinformatics Laboratories, New York, NY, ³NYU Grossman School of Medicine, Department of Medicine, Division of Rheumatology and Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, New York, NY, ⁴Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, ⁵NYU Grossman School of Medicine, Department of Pathology, Department of Medicine, Institute for Computational Medicine, New York, NY, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁷EFS, Recherche et Développement, Department of Pulmonology and Physiology, CHU Grenoble-Alpes, Université Grenoble-Alpes, INSERM U1209, CNRS UMR, Institute for Advanced Biosciences, Grenoble, France
Background/Purpose: Behçet's disease (BD) is an HLA class I-associated disorder, given its strong link to HLA-B*51. However, evidence of HLA class I restriction is lacking,…
Abstract Number: 1271 • ACR Convergence 2023
Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)
Bong-Ki Hong¹, Sungyong You², Naeun Lee¹, Jung Gon Kim³, Kijun Lee⁴, Ji Hyeon Ju⁵, Wan-Uk Kim¹ and Ho-Youn Kim⁶, ¹The Catholic University of Korea, Seoul, South Korea, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Inje University Ilsan Paik Hospital, Goyang, South Korea, ⁴YiPSCELL, Secho, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶HoYoun Kim's Clinic for Arthritis Rheumatism, Seoul, South Korea
Background/Purpose: Recent research has revealed a significant upregulation of IFNγ-related genes in RA patients, though the underlying mechanisms and implications are still unclear. To further…
Abstract Number: 2182 • ACR Convergence 2023
Mitochondrial Alterations in Primary Sjögren´s Syndrome
Pavlina Javorova¹, Johannes Fessler¹, Melanie Zeiler¹, Angelika Lackner¹, Josef Hermann², Sabine Zenz³, Jens Thiel⁴ and Martin Stradner¹, ¹Medical University of Graz, Graz, Austria, ²Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, ³Medical University Graz, Graz, Austria, ⁴University Hospital Freiburg, Freiburg, Germany
Background/Purpose: Primary Sjögren's Syndrome (pSS) is a systemic autoimmune disorder characterized by lymphocytic infiltrations in exocrine glands. T-cells are considered major players in the pathogenesis…
Abstract Number: 0066 • ACR Convergence 2023
Mitochondrial Dysfunction and Fatigue in Sjögren’s Disease
Biji T Kurien¹, Rebecca Wood², Gavin Pharaoh³, Joshua Cavett¹, Valerie Lewis¹, Bhaskaran Shylesh¹, Lida radfar¹, Astrid Rasmussen¹, Christopher Lessard¹, A. Darise Farris¹, Kathy Sivils⁴, Kristi Koelsch¹, Holly Van Remmen¹ and R Hal Scofield⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Edmond, OK, ³University of Washington, Seattle, WA, ⁴Janssen Research & Development, LLC, Edmond, OK, ⁵Oklahoma City Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Sjögren's disease (SjD) is a chronic, autoimmune condition with diminished lacrimal and salivary gland secretion leading to keratoconjunctivitis sicca and xerostomia, respectively. In addition,…
Abstract Number: 0086 • ACR Convergence 2023
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Stephen Parmley, Benjamin Szylyk, Richard Frank, Matthew Hsu, Polina Brodsky, Cailin Sibley, Paul Lizzul and Martin Dahl, AnaptysBio, San Diego, CA
Background/Purpose: Checkpoint antagonist therapeutics have transformed the field of oncology while advancing the understanding of adequate checkpoint activity in preventing autoimmunity. Checkpoint agonism represents a…
Abstract Number: 0699 • ACR Convergence 2023
T Cell Subset Analysis in Patients with Large-Vessel Vasculitis
Rebecca Kuan¹, Christopher Redmond¹, McKella Sylvester², Mary Maclean¹, Francoise Meylan¹, Marcela Ferrada¹, Kaitlin Quinn¹ and Peter Grayson³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Colgate University, Bethesda, MD, ³National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by granulomatous inflammation of the aorta and its major branches. The two major forms are giant cell arteritis (GCA)…
Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
Abstract Number: 2331 • ACR Convergence 2023
Molecular Predictors of Treatment Response in Two Trials of Abatacept in Systemic Lupus Erythematosus
Kevin Thomas¹, Miles Smith¹, Carla Guthridge¹, Nicolas Dominguez¹, Susan Macwana¹, Wade DeJager¹, Catriona Wagner¹, Peter Schafer², Stan Kamp¹, Betty Diamond³, David Wofsy⁴, Aikaterini Thanou⁵, Cristina Arriens⁶, Cynthia Aranow³, Joan Merrill¹, Judith James¹ and Joel Guthridge¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Bristol Myers Squibb, Belle Mead, NJ, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴University of California San Francisco, San Francisco, CA, ⁵University of Oklahoma Health, Edmond, OK, ⁶Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK
Background/Purpose: Abatacept (ABA) is a fusion protein that disrupts T cell co-stimulation by inhibiting interactions between CD28 and CD80/86. ABA is effective in RA, but…
Abstract Number: 020 • 2023 Pediatric Rheumatology Symposium
Generation of Human Resident Memory T Cells in 3D Synovial Organoid Model
Margaret Chang¹, Maryrose Hahn¹, Brian Wauford¹, Rachel Blaustein², Kevin Wei² and Peter Nigrovic¹, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Most rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) patients experience episodic arthritis flares and require life-long medications to control their disease. We observed…
Abstract Number: 129 • 2023 Pediatric Rheumatology Symposium
Interrogation of STAT3 Activation in Patients with Polyarticular Juvenile Arthritis (polyJIA)
Stephanie Wood¹, Justin Branch¹, Priscilla vasquez¹, Marietta De Guzman¹, Amanda Brown², A. Carmela Sagcal-Gironella³, Saimun Singla⁴, Andrea Ramirez⁵ and Tiphanie Vogel⁵, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Hackensack University Medical Center, Hackensack, NJ, ⁴Self, Houston, TX, ⁵Baylor College of Medicine, Houston, TX
Background/Purpose: A better understanding of the pathogenesis of polyJIA is necessary to guide more effective clinical care, such as the development of data-driven approaches to…
Abstract Number: L03 • ACR Convergence 2022
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
Jay Tuttle¹, Edit Drescher², Jesus Abraham Simón-Campos³, Paul Emery⁴, Maria Greenwald⁵, Alan Kivitz⁶, Hyungmin Rha¹, Pia Yachi¹, Christina Kiley¹ and Ajay Nirula⁷, ¹Eli Lilly and Company, Indianapolis, IN, ²Csolnoky Ferenc Hospital, Veszprém, Hungary, ³Köhler & Milstein Research/Hospital Agustín O'Horán, Merida, Yucatan, Mexico, ⁴University of Leeds, Leeds, United Kingdom, ⁵Desert Medical Advances, Palm Desert, CA, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Eli Lilly, San Diego, CA
Background/Purpose: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). We hypothesized that peresolimab binding to PD-1,…
Abstract Number: 0500 • ACR Convergence 2022
T Cell and Macrophage Synergy Drive Inflammatory Synovial Fibroblasts in Rheumatoid but Not Psoriatic Arthritis
Achilleas Floudas¹, conor Smith², Orla Tynan³, Nuno Neto⁴, Krishna Vinod⁵, Sarah Wade⁶, Megan Hanlon⁷, Clare Cunningham⁴, Viviana Marzaioli⁸, Mary Canavan⁹, Jean Fletcher³, Ronan Mullan¹⁰, Suzanne Cole¹¹, Ling-Yang Hao¹², Michael Monaghan⁴, Sunil Nagpal¹³, Douglas Veale¹⁴ and Ursula Fearon⁴, ¹Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ²bTrinity College Dublin, Dublin, Ireland, ³Trinity Biomedical Sciences Institute, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Janssen, Spring House, PA, ⁶Trinity Biomedical Sciences Institute, Wexford, Ireland, ⁷Molecular Rheumatology, Dublin, Ireland, ⁸Trinity College Dublin and University College Dublin, Dublin, Ireland, ⁹Trinity College, Dublin, Ireland, ¹⁰Tallaght University Hospital, Dublin, Ireland, ¹¹Rheumatic Disease Associates, Warminster, PA, ¹²Janssen Research and Development, LLC, Spring House, PA, ¹³Janssen Research, Collegeville, PA, ¹⁴St. Vincent's University Hospital, Blackrock, Dublin, Ireland
Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are common autoimmune diseases of unknown aetiology characterised by complex synovial pathology with a detrimental effect on the…
Abstract Number: 0809 • ACR Convergence 2022
Ex Vivo Comparative Immunogenicity Assessment (EVCIA) to Determine Relative Immunogenicity in Chronic Plaque Psoriasis in Participants Receiving Humira® or Undergoing Repeated Switches Between Humira and AVT02
Kathleen Richter¹, Halimuniyazi Haliduola¹, Jana Schockaert², Aurélie Mazy³, Nataliya Reznichenko⁴, Eric Guenzi⁵ and Fausto Berti⁶, ¹Alvotech, Jülich, Germany, ²ImmunXpert, Ghent, Belgium, ³ImmunXpert, Charleroi, Belgium, ⁴Military Hospital (Military Unit A3309) of Military-Medical Clinical Center of Southern Region, Zaporizhzhia, Ukraine, ⁵UGA Biopharma, Bonn, Germany, ⁶Alvotech, Zürich, Switzerland
Background/Purpose: A common reason for clinical development failure of biologic medicines is immunogenicity. Immunogenicity is traditionally measured by detecting neutralizing (NAb) anti-drug antibodies (ADA) in…
Abstract Number: 1730 • ACR Convergence 2022
T Cell-Macrophage Interactions Play a Critical Role in a Mouse Model of Histidyl-tRNA Synthetase-Induced Myositis
Daniel Reay¹, Ying Wang², Wael Jarjour³, Paula Clemens¹ and Dana Ascherman⁴, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Miami Miller School of Medicine, Miami, FL, ³The Ohio State University, Columbus, OH, ⁴University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Histidyl-tRNA synthetase (HRS) is a key target of antigen-specific B and T cell responses in the anti-synthetase syndrome. Despite a clear role for aberrant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].